



Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

November 9, 2022

SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its *Human-First Discovery®* platform to develop a novel class of orally administered biological drugs, today announced that the company will present at the following investor conferences:

- **Jefferies London Healthcare Conference**

Wednesday, November 16, 2022 at 10:55 am GMT

Corporate presentation by Howard Franklin, MD, MBA, Chief Medical Officer

- **Evercore ISI HealthCONx Conference**

Thursday, December 1, 2022 at 11:20 am ET

Fireside chat with Mark Smith, PhD, Chief Executive Officer

Live webcasts of both events will be available under the '[Investors & News](#)' section of the Finch website. Replays of the webcasts will be available on Finch's website for approximately 30 days after each event.

About Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its *Human-First Discovery®* platform to develop a novel class of orally administered biological drugs. Finch's lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent *C. difficile* infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is exploring strategic options to potentially advance the development of its pre-clinical candidates FIN-524 for ulcerative colitis and FIN-525 for Crohn's disease and its pre-clinical program in autism spectrum disorder. Finch routinely posts information that may be important to its investors on its website at www.finchterapeutics.com. Finch encourages investors to consult the "Investors & News" section of its website regularly.

Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.

Investor Contact:

Stephen Jasper

Gilmartin Group

(858) 525-2047

stephen@gilmartinir.com

Media Contact:

Jenna Urban

Berry & Company Public Relations

(212) 253-8881

jurban@berrypr.com